BUBENDORF, Switzerland, July 2, 2007 (PRIME NEWSWIRE) -- Switzerland-based CARBOGEN AMCIS AG is integrating SynProTec DCR Ltd. into its world leading drug development chemistry business.
SynProTec DCR, a custom synthesis company based in Manchester, England, will retain its current staff of experts and leadership, who will begin operating under the newly formed entity CARBOGEN AMCIS Ltd. CARBOGEN AMCIS will officially begin managing the new business arm on July 1. Both companies are owned by Dishman Pharmaceuticals and Chemicals, Limited http://www.dishmangroup.com/ and were acquired in 2006 and 2005, respectively.
SynProTec specializes in process research and custom synthesis of pharmaceutical intermediates. The larger production capacity (up to 4,500 l), which SynProTec DCR adds to the CARBOGEN AMCIS portfolio, allows the efficient production of early phase active pharmaceutical ingredients (APIs) and large scale intermediates.
"This is a natural, strategic progression for both companies," said Mark Griffiths, CEO, CARBOGEN AMCIS AG. "We have already worked together extensively over the past six months when customers needed large quantities of intermediates. By joining the two companies under a single management structure, our production capacity will increase significantly, and material produced by SynProTec DCR can be further processed at CARBOGEN AMCIS' Swiss facilities. This will allow us even greater flexibility to accommodate projects and ensure that they are performed in the most time- and cost-efficient manner."
Like CARBOGEN AMCIS, SynProTec DCR's experience in the industry spans almost 20 years. Since opening in the mid-1980s, SynProTec DCR has provided more than 400 projects covering an impressive range of organic chemistry. Products and processes developed by SynProTec DCR are operating successfully on four continents.
The added capacity for production with the integration of SynProTec DCR is one of many enhancements CARBOGEN AMCIS has deployed in 2007 alone. On the operational side, investments include hiring additional personnel to extend shifts at the Swiss sites and adding a new High Containment Analytical Laboratory at the Bubendorf site. Designed to support analytics of highly potent compounds, the lab includes nine hoods, capable of housing a range of analytical equipment to support the majority of standard processes. Meanwhile, CARBOGEN AMCIS has also introduced the Laboratory Information Management System (LIMS) at Bubendorf. (Both of the Aarau and Hunzeschwil sites already have fully integrated LIMS.) Complete LIMS integration allows CARBOGEN AMCIS to share analytical data in real-time throughout the organization and directly with the customers through secure portals at all sites.
At the Aarau site, powder X-ray diffraction capabilities were also added for monitoring polymorphic properties, an in-demand industry capability.
"We're confident that the innovative chemistry solutions we will be integrating under the new structure - as well as the recent enhancements - will benefit our customers," added Griffiths. "We look forward to formally working hand-in-hand with the expert team there. There will be continued investment at all CARBOGEN AMCIS sites, including the SynProTec DCR facility, in line with growing customer demand and the desire to remain at the forefront of scientific excellence. "
Profile
CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources.
CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.